Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in HKD (TTM)838.65m
- Net income in HKD-505.83m
- Incorporated2015
- Employees1.11k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609913
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 31 Dec 2023 | 208.67m | 13.95% |
| GIC Pte Ltd. (Investment Management)as of 11 Apr 2024 | 35.15m | 2.35% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 27.54m | 1.84% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 18.51m | 1.24% |
| RBC Global Asset Management (UK) Ltd.as of 30 Sep 2024 | 7.47m | 0.50% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 6.96m | 0.47% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 6.52m | 0.44% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 6.47m | 0.43% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 6.36m | 0.43% |
| FIL Investment Management (Hong Kong) Ltd.as of 30 Sep 2024 | 5.21m | 0.35% |
